1-[(Pyridin-4-yl)methyl]phthalazine | 501901-70-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-[(Pyridin-4-yl)methyl]phthalazine
• 英文别名: 1-(pyridin-4-ylmethyl)phthalazine
• CAS: 501901-70-8
• 化学式: C₁₄H₁₁N₃
• 分子量: 221.26
• InChiKey: WHOWNXIYXLWMGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS<br/>[FR] SPIROÉTHERS MACROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE MCL-1
  申请人：ASCENTAGE PHARMA SUZHOU CO LTD

  公开号：WO2020147802A1

  公开（公告）日：2020-07-23

  Provided are compounds represented by Formula (I-A) and the pharmaceutically acceptable salts and solvates thereof, wherein R8, R9a, R9b, R9c, R9d, X, Y, Z, Z1, W, and (aa) are as defined as set forth in the specification. Provided are also compounds of Formula (I-A) for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.

  提供的是由公式（I-A）表示的化合物以及其中所述的药物可接受的盐和溶剂化物，其中R8，R9a，R9b，R9c，R9d，X，Y，Z，Z1，W和（aa）如说明书所述定义。还提供了用于治疗对Mcl-1抑制有反应的条件或疾病的公式（I-A）化合物，例如癌症。
• [EN] 5, 6-DIHYDRO-11H-INDOLO [2, 3-B] QUINOLIN-11-ONE COMPOUNDS AS ALK INHIBITORS<br/>[FR] COMPOSÉS DE 5, 6-DIHYDRO-11H-INDOLO [2, 3-B] QUINOLÉIN-11-ONE UTILES EN TANT QU'INHIBITEURS D'ALK
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2019179482A1

  公开（公告）日：2019-09-26

  The present disclosure provides compounds represented by Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7, R8, E, Z, and are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.

  本公开提供了由式（I）表示的化合物及其药用可接受的盐和溶剂，其中R1a、R1b、R2a、R2b、R3、R4、R5、R6、R7、R8、E、Z等如规范中所定义。本公开还提供了式（I）的化合物，用于治疗对ALK抑制有响应的疾病或疾病，如癌症。
• [EN] MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS<br/>[FR] PYRRAZOLES FUSIONNÉS MACROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE MCL-1
  申请人：ASCENTAGE PHARMA SUZHOU CO LTD

  公开号：WO2020151738A1

  公开（公告）日：2020-07-30

  Provided are compounds represented by Formula IA: (IA), and the pharmaceutically acceptable salts and solvates thereof, wherein R, R 1a, R 1b, L 1, L 2, L 3, X, A, B and C are as defined as set forth in the specification. Also provided compounds of Formula IA for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.

  提供由化学式IA表示的化合物，以及其在药学上可接受的盐和溶剂化合物，其中R、R 1a、R 1b、L 1、L 2、L 3、X、A、B和C的定义如规范中所述。还提供了化学式IA的化合物，用于治疗对Mcl-1抑制敏感的疾病或紊乱，如癌症。
• Somatostatin analogues
  申请人：Albert Rainer

  公开号：US20050014686A1

  公开（公告）日：2005-01-20

  The invention provides cyclo[ 4 -(NH 2 —C 2 H 4 —NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr( 4 -Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.

  该发明提供了cyclo[4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe]，可选地以保护形式存在，或其药学上可接受的盐或配合物，具有有趣的药物特性。
• New pharmaceutical combination
  申请人：Schuppan Detlev

  公开号：US20050054647A1

  公开（公告）日：2005-03-10

  Pharmaceutical combinations comprising at least one compound of general formula I-A or I-AA, and at lest one compound of general formula II) or Iia), or pharmaceutical combinations comprising at least one compound of general formula I-A or I-AA, and at least one compound of general formula II) or Iia), and an anti-hormone, and their use for the treatment of different diseases resulting by persistent angiogenesis are described.

  本文描述了包含至少一个I-A或I-AA通用式化合物和至少一个II）或Iia）通用式化合物的制药组合物，或包含至少一个I-A或I-AA通用式化合物和至少一个II）或Iia）通用式化合物以及抗激素的制药组合物，并用于治疗由持续血管生成引起的不同疾病。